Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

10%

1 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A

4(44.4%)

Phase 2

4(44.4%)

Phase 3

1(11.1%)

9Total

N/A(4)

Phase 2(4)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT07486830Phase 2Recruiting

IncobotulinumtoxinA for Provoked Vestibulodynia With Overactive Pelvic Floor Muscle Dysfunction

Role: lead

NCT07257029Phase 2Recruiting

Topical Ketotifen 0.25% for Secondary Vestibulodynia

Role: lead

NCT06360705Not ApplicableCompleted

StrataMGT for the Treatment of Vulvar Lichen Sclerosus

Role: lead

NCT03665584Not ApplicableCompleted

MonaLisa Touch Laser for the Treatment of Vulvar Lichen Sclerosus

Role: lead

NCT03782480Phase 3Unknown

Examining Effects of Intrarosa in Women With Genitourinary Syndrome of Menopause/Vulvovaginal Atrophy

Role: lead

NCT03045172Not ApplicableCompleted

Platelet Rich Plasma (PRP) for Vulvar Lichen Sclerosus

Role: lead

NCT03561428Unknown

Biomarkers of Lichen Sclerosus

Role: lead

NCT03189238Phase 2Unknown

Platelet Rich Plasma (PRP) Peri-urethral and Clitoral Injections for the Treatment of Female Orgasmic Disorder

Role: lead

NCT02794363Not ApplicableCompleted

Platelet Rich Plasma Injections for Vulvar Lichen Sclerosus

Role: lead

NCT00393263Phase 2Completed

Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus

Role: lead

All 10 trials loaded